Cell and Gene Therapy, Industrial Impact

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

March 22, 2023

Making the Promise of mRNA
If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Spotlight

Gema Biotech

With a strong R&D Platform and four production sites, AMEGA Biotech develops and produces biotech products. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer. Our work and vision are directed forward, based on a comprehensive design and integration of all the processes involved in the production of high quality and high technology products, from Active Pharmaceutical Ingredient to the Finished Dosage Form.

OTHER WHITEPAPERS
news image

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

Read More
news image

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

Read More
news image

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

Read More
news image

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Read More
news image

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

Read More
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More

Spotlight

Gema Biotech

With a strong R&D Platform and four production sites, AMEGA Biotech develops and produces biotech products. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer. Our work and vision are directed forward, based on a comprehensive design and integration of all the processes involved in the production of high quality and high technology products, from Active Pharmaceutical Ingredient to the Finished Dosage Form.

Events